M
Miao Miao
Researcher at Soochow University (Suzhou)
Publications - 94
Citations - 564
Miao Miao is an academic researcher from Soochow University (Suzhou). The author has contributed to research in topics: Hematopoietic stem cell transplantation & Transplantation. The author has an hindex of 10, co-authored 72 publications receiving 337 citations.
Papers
More filters
Journal ArticleDOI
Maintenance therapy with decitabine after allogeneic hematopoietic stem cell transplantation to prevent relapse of high-risk acute myeloid leukemia.
Yunju Ma,Changju Qu,Haiping Dai,Jia Yin,Zheng Li,Jia Chen,Huiying Qiu,Aining Sun,Miao Miao,Chengcheng Fu,Zhengming Jin,Xiaming Zhu,Depei Wu,Xiaowen Tang +13 more
TL;DR: This study hypothesized that administration of DAC after allo-HSCT may reduce relapse in patients with high-risk AML and conducted a retrospective, paired controlled study to assess safety and efficacy.
Journal ArticleDOI
Donor-derived anti-CD19 CAR T cells compared with donor lymphocyte infusion for recurrent B-ALL after allogeneic hematopoietic stem cell transplantation
Jingsheng Hua,Jian Zhang,Xinyou Zhang,Xiaoxia Wu,Lili Zhou,Xiebing Bao,Yue Han,Miao Miao,Caixia Li,Chengcheng Fu,Suning Chen,Xiaowen Tang,Depei Wu,Huiying Qiu +13 more
TL;DR: It is suggested that donor-derived anti-CD19 CAR T-cell therapy is promising, safe, and potentially effective for relapsed B-ALL after allo-HSCT and may be superior to DLI.
Journal ArticleDOI
Haploidentical hematopoietic stem cell transplant in paroxysmal nocturnal hemoglobinuria
Hong Tian,Liming Liu,Jia Chen,Yang Xu,Zhengming Jin,Miao Miao,Zhengzheng Fu,Huiying Qiu,Aining Sun,Depei Wu +9 more
TL;DR: It is suggested that allo-HSCT is a promising treatment for PNH, and HRD-HS CT is a viable option for patients with PNH who lack HLA-matched donors.
Journal Article
[Clinical study of umbilical cord-derived mesenchymal stem cells for treatment of nineteen patients with steroid-resistant severe acute graft-versus-host disease].
Guanghua Chen,Ting Yang,Hong Tian,Man Qiao,Hui-Wen Liu,Chengcheng Fu,Miao Miao,Zheng-Min Jin,Xiaowen Tang,Yue Han,Guangsheng He,Xu-hui Zhang,Xiao Ma,Feng Chen,Xiaohui Hu,Shengli Xue,Ying Wang,Huiying Qiu,Aining Sun,Zhi-zhe Chen,Depei Wu +20 more
TL;DR: In this article, the safety and efficacy of umbilical cord-derived mesenchymal stem cells (MSCs) infusion in patients with severe acute graft-versus-host disease (aGVHD) was evaluated.
Journal ArticleDOI
Clinical study of umbilical cord-derived mesenchymal stem cell for treatment of nineteen patients with steroid-resistant severe acute graft-versus-host disease
TL;DR: Infusion of umbilical cord-derived MSCs expanded in vitro is an effective therapy for patients with steroid-resistant severe aGVHD without negative impact on relapse and freshly prepared M SCs are superior to frozen and thawed cells in terms of cell viability.